In 234 children and adolescents (6-17 years) with episodic migraine, monthly fremanezumab versus placebo for 3 months cut migraine days per month by 2.5 vs 1.4 (difference 1.1; P=0.02); injection-site erythema was the most common adverse event (9.8% vs 5.4%).
RCTn = 237
Hershey et al. Fremanezumab in Children and Adolescents with Episodic Migraine